| Why Did Board Insiders Recently Buy More Than 500,000 Shares of This Company’s Stock? |
| |
|
Florida-based biopharma CTD Holdings (OTCQB: CTDH) saw a wave of insider buying from its board members over the last several weeks.
Over a 45-day period, the company’s board members purchased more than 500,000 shares of CTDH common stock in the open market, with 90% of the shares purchased by independent, outside directors.
The timing of the latest purchases followed the company’s announcements earlier in July 2019 regarding the treatment of an Alzheimer’s patient with its drug candidate for more than a year under an FDA compassionate use program, and the Company’s endorsement of Alzheimer's Disease as its next drug development indication.
The Backstory: CTD Holdings, which plans to change its name to Cyclo Therapeutics, is developing cyclodextrin-based products for the treatment of disease with unmet medical need.
The company has been intravenously administering its proprietary Trappsol® Cyclo™ product to an Alzheimer’s patient for more than a year. In a required annual report to the FDA filed in June 2019, CTDH reported data that suggests a positive safety profile in this patient, overall stabilization of disease, and improvement in certain behavioral aspects of the disease. Given that persons with Alzheimer's Disease dementia are generally expected to decline during a one-year timeframe, the results with this patient are extremely promising.
Based on data from this case, the company’s Scientific Advisory Board formally endorsed plans to move forward with the launch of a clinical trial in Alzheimer’s in July. Insiders began adding to their positions in the weeks that followed the Company’s public announcements.
Independent Directors Added 865,000 Shares to Already Large Positions
Board member Markus Sieger, President and CEO of Polpharma Group, purchased 100,000 shares in August, increasing his total position to more than 4.5 million shares. Polpharma is among the top 20 generic drug manufacturers in the world. Its portfolio includes about 600 products and another 200 in development.
Patrick Ostronic, an officer of US Pharmacia International and CFO of its parent company, The USP Group, personally purchased 350,000 shares of CTDH in the weeks following the company announcing its plans to launch an Alzheimer’s trial. As of the latest filing, Ostronic himself owned more than 1.2 million shares of CTDH. USP has been a trend setter in the OTC medicine market for over 20 years and is currently the leading company in the OTC sector of the Polish pharmaceutical market, employing around 700 people across Eastern Europe and the United States with a portfolio of more than 100 products.
Former President & COO of Colgate-Palmolive Owns 2.5M+ Shares
Also serving on CTDH’s board is William Shanahan, the retired President and COO of Colgate-Palmolive. Shanahan joined CTDH’s board in 2016 and now owns more than 2.5 million shares of CTDH as of the latest filings, which include his 800,000 share purchase in May 2019 and his purchase of 415,000 shares in August and September 2019.
Collectively to date, CTDH insiders have invested approximately $10 million into the company.
When the people close to operations are heavily invested, it is often for good reason and warrants investor attention.
Learn more about CTDH, its work on Alzheimer’s, and its Phase I/II trials for an orphan genetic disease called Niemann-Pick Disease Type C, by visiting CTDHinfo.com.
Chairman & CEO Adds to Position
CTDH’s Chairman and CEO, Scott Fine, also added to his position in recent weeks, purchasing another 50,000 shares that takes his total ownership to more than 6.7 million shares.
Fine has been a director of CTDH since February 2014 and became the company’s CEO in September 2015. He has been involved in investment banking for over 35 years, with much of his time focused on transactions in the healthcare and consumer products arenas.
Disclosure
CTD Holdings (CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Can-Fite Biopharma (NYSE American: CANF) Strikes Deal with Univo to Develop Cannabinoid-Based Treatments for a Variety of Diseases |
| |
|
It is widely recognized that the identification of specific receptors and pathways through which CBD operates is expected to greatly enhance the development of CBD-based pharmaceuticals. Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the CBD market, based on findings published in peer reviewed scientific journals demonstrating that CBDs bind to the Gi protein-coupled A3 adenosine receptor (A3AR), which is over-expressed in pathological cells. Can-Fite is a global leader in the research and development of drugs that target A3AR.
Why It Matters: It is widely recognized that the identification of specific receptors and pathways through which CBD operates is expected to greatly enhance the development of CBD-based pharmaceuticals. Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the CBD market, based on findings published in peer reviewed scientific journals demonstrating that CBDs bind to the Gi protein-coupled A3 adenosine receptor (A3AR), which is over-expressed in pathological cells. Can-Fite is a global leader in the research and development of drugs that target A3AR.
Key Quote: “This collaboration provides Can-Fite with new and very exciting business opportunities for utilizing our technology platform and expertise.” – Dr. Pnina Fishman, CEO
What’s Next: Dawson James initiated research coverage of Can-Fite with a buy rating and $9 price target. The stock currently trades for around $2.60 per share.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of RedChip investor awareness services and consulting services. RedChip Companies also owns 16,500 shares of CANF Rule 144 stock, acquired in August 2019.
|
|
| |
|
| CTD Holdings (OTCQB: CTDH) to Present on Its Clinical and Drug Development Program for the Orphan Drug Trappsol® Cyclo™ |
| |
|
CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK (NPUK) 10th Interactive Workshop on Niemann-Pick Diseases and the 26th Annual NPUK Family Conference.
Why It Matters: Niemann-Pick Disease Type C (NPC) is a rare and fatal genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell. Because of the NPC protein defect in this disease, cholesterol accumulates abnormally in every cell in the body, causing symptoms in the brain, liver, spleen, lung and other organs.
CTD's presentations at the conference will include data from its Phase I safety and tolerability trial based in the United States utilizing intravenous administration of Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of NPC (NCT02939547) and from its Phase I/II safety and efficacy trial based in the UK, Sweden, Israel and Italy using the same drug and also with intravenous administration (NCT02912793). Both trials are in the final stage of recruiting patients. An extension trial for the Phase I US-based trial is underway (NCT03893071): the extension trial allows for home-based infusions by skilled health care professionals.
The Backstory: CTDH’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials. The Company’s Scientific Advisory Board endorsed Alzheimer’s Disease (AD) as the company’s next drug development indication. The Company was authorized by the FDA to use Trappsol® Cyclo™ for a late-onset AD patient under a Compassionate Use Program which began intravenous dosing in May 2018. Program costs for the AD program are 100% funded by an external organization. With a $500M+ annual addressable market in NPC and a $1B+ annual addressable market in AD, CTDH offers a compelling opportunity for potential upside from its current valuation.
Disclosure
CTD Holdings (CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| SPI Energy Announces Closing on the Belvedere Solar Project |
| |
|
SPI Energy Co., Ltd. (NASDAQ: SPI), a global provider of photovoltaic (“PV”) solutions for business, residential, government and utility customers and investors, has announced the closing on the Belvedere project from the previously announced framework agreement to acquire up to eight solar projects in the state of Oregon (the “Oregon Portfolio”). The acquired Belvedere project is a ground-mounted PV project, located in Marion County, Oregon and it is expected to produce approximately 3.56MW of clean energy for the local community. Upon project completion, the Company expects to sell the power to Portland General Electric.
Key Quote: "This is the third PV project within the Oregon Portfolio that we have acquired. We are committed to growing our solar projects pipeline in the United States; and are accelerating our efforts to explore similar acquisition opportunities.” — Xiaofeng Peng, Chief Executive Officer of SPI Energy
What’s Next: SPI Energy Co., Ltd. is a global provider of PV solutions for business, residential, government and utility customers and investors. The Company develops solar PV projects that are either sold to third party operators or owned and operated by the Company for selling of electricity to the grid in multiple countries in Asia, North America and Europe. The Company’s subsidiary in Australia primarily sells solar PV components to retail customers and solar project developers. The Company has its operating headquarters in Santa Clara, California and maintains global operations in Asia, Europe, North America and Australia.
Disclosure
SPI Energy (SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 5,000 shares of Rule 144 stock and a monthly cash fee for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Nemaura Medical to Hold Symposium at EASD in Barcelona on Thursday, September 19, 2019 |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, has announced that Dr. Faz Chowdhury, Chief Executive Officer, Dr. Fred Schaebsdau, VP Strategic Alliances, and Dr Iain Cranson, a diabetes specialist based in the UK, will be presenting at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) on Thursday, September 19, 2019 at 18:45 - 20:15 Central European Time at the Fira Barcelona Gran Via (Maimonides Hall) in Barcelona, Spain. The evening symposium will focus on the historic development of SugarBEAT®, its application to all categories of diabetics and diabetes management, clinical data and recent user experiences. The presentation is titled: “SugarBEAT® Non-Invasive CGM User Study Results: Diagnostic and Monitoring Applications Across Different Patient Types and Clinical Settings.”
Key Quote: "We are very pleased to be holding this symposia at this premier industry conference. We will be reporting study results from our first users, as well as sharing prior clinical data and user experiences. We also plan to discuss our commercial launch plans, including product availability in different territories. We look forward to highlighting how SugarBEAT® differs from current invasive CGM technologies and the potential to expand the addressable market to include Type 2 diabetics and pre-diabetics.” — Dr. Faz Chowdhury, CEO of Nemaura
The Backstory: The EASD Annual Meeting is Europe’s largest and most prominent meeting on diabetes. The 55th Annual Meeting is being held September 16-20, 2019 at the Fira Barcelona Gran Via, Spain. The scientific program offers researchers and healthcare professionals the opportunity to share ideas and learn about cutting-edge research and technology, groundbreaking studies and the significant advances in diabetes research, treatment and care. Additional information is available at: www.easd-industry.com.
About Nemaura Medical: Nemaura Medical, Inc. is a medical technology company commercializing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading. SugarBEAT® consists of a daily, disposable adhesive skin-patch connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day. For more information, visit www.NemauraMedical.com and www.SugarBEAT.com.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for six months of investor awareness services. RedChip also received 20,000 shares of Rule 144 stock for services performed between December 2018 and May 2019.
|
|
| |
|
| |
| Quote of the Week |
| |
"We must get a sense of cash flow, asset burn, cash burn."
- Dave Maley, Manager Ariel Discovery Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
